Identifying Modifiers of EGFR Induced Tumorigenesis to Develop New Therapeutic Strategies for Lung Cancer

鉴定 EGFR 诱导肿瘤发生的修饰物以开发新的肺癌治疗策略

• 批准号: 486395
• 负责人: Jajarmi Jana
• 金额: $ 1.27万
• 依托单位: University of British Columbia
• 依托单位国家: 加拿大
• 项目类别: Studentship Programs
• 财政年份: 2022
• 资助国家: 加拿大
• 起止时间: 2022-12-01 至 2023-12-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=486395&lang=en
• 关键词: Cooperative Drivers; Crispr; Egfr; Genetics; Non-Small Cell Lung Cancer

Lung cancer is the most common type of cancer and is responsible for nearly a quarter of all cancer deaths in Canada. Targeted therapies are drugs that specifically work to shut down mutated genes that cancer cells rely on to multiply and survive. For exa

肺癌是最常见的癌症类型，占加拿大所有癌症死亡人数的近四分之一。靶向治疗是专门用于关闭癌细胞赖以繁殖和生存的突变基因的药物。例如，